Rishabh Instruments Limited has completed the allotment of 15,740 equity shares under its Employee Stock Option Plan 2022 – Scheme B to eligible employees. The Board of Directors approved this allotment through a circular resolution passed on February 4, 2026.

Share Capital Enhancement

The allotment has resulted in an increase in the company's paid-up equity share capital. The impact on the company's capital structure is detailed below:

ESOP Allotment Details

The shares were allotted under the Rishabh Instruments Limited Employee Stock Option Plan 2022 – Scheme B. Key details of the allotment include:

Regulatory Compliance

The company has fulfilled all regulatory requirements for the ESOP allotment. The newly allotted equity shares rank pari-passu with the existing equity shares of the company, ensuring equal rights and privileges for all shareholders.

The company filed the required statement under Regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with both BSE Limited and National Stock Exchange of India Limited on January 17, 2024, receiving filing numbers 192999 and 39556 respectively.

Share Characteristics

The allotted shares are identical in all respects to the existing shares and do not carry any lock-in restrictions. The shares will be listed on both BSE Limited (Scrip Code: 543977) and National Stock Exchange of India Limited (Symbol: RISHABH), where the company's equity shares are currently traded.

This ESOP allotment demonstrates the company's commitment to employee participation in its growth story while maintaining compliance with all applicable securities regulations.

Rishabh Instruments Limited has delivered exceptional financial performance in Q3FY26, with consolidated net profit surging 138% to ₹200 million and EBITDA more than doubling to ₹315 million. The company demonstrated strong operational leverage with EBITDA margin expanding significantly to 17.16% from 7.89% in the corresponding quarter last year.

Consolidated Financial Performance

The company's consolidated operations showed robust growth across key financial metrics. Revenue reached ₹1.84 billion compared to ₹1.8 billion in the year-ago quarter, while the substantial improvement in profitability metrics reflects enhanced operational efficiency and strong business execution.

Management Commentary and Business Outlook

Commenting on the Q3 and 9MFY26 results, Mr. Dineshkumar Musalekar, Whole Time Director, highlighted the company's diversified growth strategy. "Our consolidated revenue grew 1.30% YoY in Q3FY26 and 7.00% in 9MFY26, supported by product expansion and steady demand across key markets. Consolidated EBITDA margins expanded by 920 bps, with EBITDA increasing 119.50% YoY in Q3FY26, driven by sourcing efficiencies, operational improvements, and operating leverage."

Operational Excellence and Strategic Initiatives

The standout performance was driven by significant margin expansion, with EBITDA margin improving by over 900 basis points year-on-year. Rishabh Standalone revenue increased 3.10% YoY in Q3FY26 and 10.60% YoY in 9MFY26 respectively, led by strong export growth. Continued cost optimization resulted in a standalone adjusted EBITDA margin of 26.30% in Q3FY26.

Lumel SA delivered strong growth of approximately 22.40% YoY in Q3FY26, supported by product diversification and geographic expansion. The EEI business recorded robust growth, with revenue up 17.70% in Q3FY26 and 14.00% in 9MFY26, alongside strong EBITDA expansion.

Board Meeting and Results Approval

Rishabh Instruments Limited conducted its board meeting on February 5, 2026, to consider and approve the quarterly financial results. The meeting was held through video conferencing from 2:30 PM to 3:40 PM IST, in accordance with regulatory requirements under SEBI listing obligations. The company subsequently released a comprehensive results presentation on February 6, 2026, providing detailed insights into its financial performance and strategic direction.

Global Expansion and Future Growth

The company remains confident in its growth trajectory, supported by a diversified business model and expanding global footprint across the Middle East, South Africa, South America, and Southeast Asia, where it is seeing encouraging traction. The HPDC business saw a planned revenue decline due to the phased exit from loss-making legacy contracts; however, 9MFY26 EBITDA improved to ₹64 million from a loss of ₹151 million last year, in line with expectations.